Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
2.
Cancer Res ; 71(22): 7038-47, 2011 Nov 15.
Article in English | MEDLINE | ID: mdl-22006999

ABSTRACT

Hepatoma-derived growth factor (HDGF) is a secreted heparin-binding growth factor that has been implicated in cancer development and progression. Here, we report that HDGF is a critical target for transcriptional repression by the tumor suppressor p53. Endogenous HDGF expression was decreased in cancer cells with introduction of wild-type p53, which also downregulated HDGF expression after DNA damage. In support of the likelihood that HDGF is a critical driver of cancer cell growth, addition of neutralizing HDGF antibodies to culture media was sufficient to block cell growth, migration, and invasion. Similarly, these effects were elicited by conditioned culture medium from p53-expressing cells, and they could be reversed by the addition of recombinant human HDGF. Interestingly, we found that HDGF was overexpressed also in primary gastric, breast, and lung cancer tissues harboring mutant p53 genes. Mechanistic investigations revealed that p53 repressed HDGF transcription by altering HDAC-dependent chromatin remodeling. Taken together, our results reveal a new pathway in which loss of p53 function contributes to the aggressive pathobiological potential of human cancers by elevating HDGF expression.


Subject(s)
Intercellular Signaling Peptides and Proteins/physiology , Tumor Suppressor Protein p53/physiology , Cell Line, Tumor , Cell Movement , Doxorubicin/pharmacology , Humans , Hydroxamic Acids/pharmacology , Intercellular Signaling Peptides and Proteins/analysis , Intercellular Signaling Peptides and Proteins/genetics , Neoplasm Invasiveness , Promoter Regions, Genetic
3.
J Biol Chem ; 284(2): 872-83, 2009 Jan 09.
Article in English | MEDLINE | ID: mdl-19001418

ABSTRACT

p73 and p63 are members of the p53 gene family that play an important role in development and homeostasis, mainly by regulating transcription of a variety of genes. We report here that apolipoprotein D (apoD), a member of the lipocalin superfamily of lipid transport proteins, is a direct transcriptional target of the p53 family member genes. We found that the expression of apoD was specifically up-regulated by either TAp73 or TAp63 but not significantly by p53. In addition, apoD transcription is activated in response to cisplatin in a manner dependent on endogenous p73. By using small interference RNA designed to target p73, we demonstrated that silencing endogenous p73 abolishes induction of apoD transcription following cisplatin treatment. We also identified a p73/p63-binding site in the promoter of the apoD gene that is responsive to the p53 family members. The ectopic expression of TAp73 as well as the addition of recombinant human apoD to culture medium induced the osteoblastic differentiation of the human osteosarcoma cell line Saos-2, as assessed by alkaline phosphatase activity. Importantly, apoD knockdown abrogated p73-mediated alkaline phosphatase induction. Moreover, TAp73-mediated apoD expression was able to induce morphological differentiation, as well as expression of neuronal markers, in the human neuroblastoma cell line SH-SY5Y. These results suggest that apoD induction may mediate the activity of p73 in normal development.


Subject(s)
Apolipoproteins D/metabolism , Gene Expression Regulation/genetics , Trans-Activators/metabolism , Transcription Factors/metabolism , Tumor Suppressor Protein p53/metabolism , Zebrafish Proteins/metabolism , Animals , Apolipoproteins D/genetics , Base Sequence , Cell Differentiation , Cell Proliferation , Cells, Cultured , Humans , Mice , Neuroblastoma/genetics , Neuroblastoma/metabolism , Neuroblastoma/pathology , Osteoblasts/cytology , Osteoblasts/metabolism , Protein Binding , RNA, Messenger/genetics , Trans-Activators/classification , Trans-Activators/genetics , Transcription Factors/classification , Transcription Factors/genetics , Tumor Suppressor Protein p53/classification , Tumor Suppressor Protein p53/genetics , Zebrafish Proteins/classification , Zebrafish Proteins/genetics
4.
Mol Cancer Ther ; 7(4): 779-87, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18413792

ABSTRACT

Therapeutic replacement of the wild-type p53 gene has been pursued as a potential gene therapy strategy in a variety of cancer types; however, some cancer models are resistant to p53 in vivo and in vitro. Therefore, to improve p53 gene therapy, it is important to overcome the resistance to p53-mediated apoptosis. Histone deacetylase inhibitors are a novel class of chemotherapeutic agents that are able to reverse the malignant phenotype of transformed cells. A natural histone deacetylase inhibitor, FK228, is reported to enhance adenovirus infection due in part to the up-regulation of coxsackievirus adenovirus receptor expression. In this study, preclinical experiments were done to establish a mechanistic rationale for the combination of adenovirus-mediated p53 family gene transfer and FK228 pretreatment in future clinical trials. Pretreatment with FK228 enhanced apoptosis in human cancer cells through enhanced transduction of Ad-p53. FK228 also induced hyperacetylation of the p53 protein and specifically enhanced p53-mediated Noxa expression. Additionally, the combination of FK228 and Ad-p53 induced Bax translocation to the mitochondria. The double knockdown of Bax and Noxa expression by small interfering RNA antagonized the synergistic effect of Ad-p53 and FK228 on apoptosis induction. In human cancer xenograft models, FK228 significantly increased the therapeutic effectiveness of p53 as well as p63 gene therapy. These results provide a strong rationale for combining p53 gene therapy and FK228 pretreatment in cancer therapy.


Subject(s)
Antibiotics, Antineoplastic/therapeutic use , Colorectal Neoplasms/therapy , Depsipeptides/therapeutic use , Disease Models, Animal , Genetic Therapy , Histone Deacetylase Inhibitors , Stomach Neoplasms/therapy , Tumor Suppressor Protein p53/genetics , Acetylation , Adenoviridae/genetics , Animals , Apoptosis/drug effects , Apoptosis/physiology , Colorectal Neoplasms/genetics , Colorectal Neoplasms/pathology , DNA-Binding Proteins/metabolism , Fluorescent Antibody Technique , Histone Deacetylases/metabolism , Humans , Immunoblotting , Mice , Mice, Nude , Nuclear Proteins/metabolism , Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins c-bcl-2/metabolism , RNA, Small Interfering/pharmacology , Stomach Neoplasms/genetics , Stomach Neoplasms/pathology , Trans-Activators/metabolism , Transcription Factors , Tumor Cells, Cultured , Tumor Suppressor Protein p53/metabolism , Tumor Suppressor Proteins/metabolism , bcl-2-Associated X Protein/antagonists & inhibitors , bcl-2-Associated X Protein/genetics , bcl-2-Associated X Protein/metabolism
5.
Cancer Biol Ther ; 6(7): 1058-66, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17568187

ABSTRACT

Osteosarcoma (OS) is one of the most common malignancies of the bone. Although prognosis of OS has improved significantly during the past several years due to more intensive chemotherapy and radiotherapy regimens, new therapeutic approaches are needed for recurrent and inoperable cases, p73 and p63, like their homologue, the tumor suppressor p53, are able to induce apoptosis in several cell types. Here, we evaluated the antitumor effects of p73 and p63 on eleven different human OS cell lines. In vitro, adenovirus-mediated transduction of p63gamma induced apoptosis in OS cells that are resistant to p53-mediated apoptosis, while less effect was observed following transduction of p73alpha or p63alpha. Interestingly, the apoptotic effects of p63gamma were greater than those of wild-type p53 in OS cells carrying MDM2-amplification. We then determined the in vivo therapeutic effect of intratumoral injection of adenovirus-vector expressing p53 family members on xenografts derived from Saos-2 cells implanted in nude mice, and showed that infection with p63y significantly suppressed tumor growth compared with p53. In addition, exogenous p73beta and p63gamma significantly increased the chemosensitivity of OS cells to doxorubicin and cisplatin, chemotherapeutic agents commonly used in the treatment of OS. Our results suggest that adenovirus-mediated transduction of p53 family members may have utility in gene therapy for OS, particularly in combination with chemotherapeutic agents.


Subject(s)
Adenoviridae/genetics , Bone Neoplasms/therapy , Genes, p53 , Genetic Therapy , Osteosarcoma/therapy , Animals , Apoptosis , Bone Neoplasms/pathology , Cell Line, Tumor , DNA-Binding Proteins/genetics , Female , Humans , Membrane Proteins/genetics , Mice , Mice, Inbred BALB C , Nuclear Proteins/genetics , Osteosarcoma/pathology , Proto-Oncogene Proteins c-mdm2/genetics , Tumor Protein p73 , Tumor Suppressor Proteins/genetics , Xenograft Model Antitumor Assays
6.
Eur J Haematol ; 69(5-6): 297-302, 2002.
Article in English | MEDLINE | ID: mdl-12460234

ABSTRACT

OBJECTIVES: Pre-eclampsia is associated with changes in the hemostatic system and endothelial status. Urinary 11-dehydrothromboxane B2/creatinine (11-DTXB2/Cr) is a marker for platelet activation and vascular constriction, thrombin-antithrombin complex (TAT) for thrombin formation, serum thrombomodulin (TM) for endothelial damage, and beta-thromboglobulin (beta-TG) and platelet factor 4 (PF-4) for platelet activation and releasing reaction. The present study attempted to evaluate these five markers in normotensive pregnancy and pre-eclampsia. METHODS: These five markers were simultaneously measured in urine and blood samples from 25 women who were not pregnant (group 1, controls), 31 women with normotensive pregnancy (group 2, second controls), 22 women with mild pre-eclampsia (group 3), and 21 women with severe pre-eclampsia (group 4). The average gestational age was 36 wk. RESULTS: The 11-DTXB2/Cr, TAT, and beta-TG levels were significantly higher (P < 0.01) in groups 2, 3, and 4 than in group 1. The TM and beta-TG levels were significantly higher (P < 0.05) in group 3 than in group 2. The TM, beta-TG, and PF-4 levels were increased significantly (P < 0.05-0.01) in group 4 compared to those in groups 1, 2, and 3. CONCLUSION: Platelet aggregation, vascular constriction, and thrombin formation (detected by 11-DTXB2/Cr and TAT) may be markedly enhanced even in group 2, but further enhancement may be relatively slight in groups 3 and 4. In contrast, endothelial damage (determined by TM) and platelet release of PF-4 may not increase significantly in group 2, but they may increase in group 4. Platelet-release of beta-TG may be enhanced in groups 2, 3, and 4. Endothelial damage and platelet-releasing reaction (detected by PF-4 and beta-TG) may be significantly more enhanced in group 4 than in group 3.


Subject(s)
Hemostasis/physiology , Pre-Eclampsia/blood , Thromboxane B2/analogs & derivatives , Adult , Antithrombin III/urine , Biomarkers/blood , Biomarkers/urine , Blood Pressure , Case-Control Studies , Endothelium, Vascular/metabolism , Female , Humans , Peptide Hydrolases/blood , Peptide Hydrolases/urine , Platelet Count , Platelet Factor 4/analysis , Platelet Factor 4/urine , Pre-Eclampsia/physiopathology , Pre-Eclampsia/urine , Pregnancy , Thrombomodulin/analysis , Thrombomodulin/blood , Thromboxane B2/blood , Thromboxane B2/urine , beta-Thromboglobulin/analysis , beta-Thromboglobulin/urine
7.
Acta Obstet Gynecol Scand ; 81(3): 208-13, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11966476

ABSTRACT

BACKGROUND: Urinary 11-dehydrothromboxane B(2)/creatinine (11-DTXB(2)/Cr) is a marker for in vivo platelet activation and vascular constriction, blood thrombomodulin (TM) for endothelial damage and associated thrombosis, thrombin-antithrombin complex (TAT) for thrombin formation, and beta-thromboglobulin (beta-TG) and platelet factor 4 (PF-4) for in vivo platelet activation and releasing reaction. Little is known about the quantitative relationship among them during pregnancy. The present study investigated levels of five markers at different stages of normotensive pregnancy. METHODS: Subjects were 17 healthy non-pregnant women (Group 1, control) and 67 women carrying single fetuses in normotensive pregnancy. Of the pregnant women, 17 were in the 20th week of gestation (Group 2), 20 were in their 30th week (Group 3), and 30 were in their 36th week (Group 4). Urinary and circulating blood levels of 11-DTXB(2)/Cr, TM, TAT, beta-TG, and PF-4 were measured simultaneously. RESULTS: The 11-DTXB(2)/Cr and TAT levels showed elevated values at the 20th and 30th weeks of gestation, and markedly elevated values at the 36th week, whereas the TM level remained constant throughout pregnancy. The beta-TG and PF-4 levels maintained stable values at the 20th week, but showed elevated values at the 30th and 36th weeks. CONCLUSIONS: Platelet aggregation, vascular constriction, and thrombin formation (detected by 11-DTXB(2)/Cr and TAT) appear to be enhanced as early as the 20th week of gestation, continuously enhanced by the 30th week, and markedly enhanced by the 36th week. Platelet activation and releasing reaction (determined by beta-TG and PF-4) gradually enhanced from the 30th to 36th weeks. In contrast, endothelial damage and associated thrombosis (detected by TM) were minimal throughout pregnancy. Investigating these markers of hemostasis and endothelial function in normotensive pregnancy may provide insights into related disease states.


Subject(s)
Antithrombin III/analysis , Blood Pressure/physiology , Coagulants/blood , Creatinine/urine , Endothelium/physiology , Hemostasis/physiology , Peptide Hydrolases/blood , Platelet Factor 4/analysis , Pregnancy/blood , Pregnancy/urine , Thrombomodulin/blood , Thromboxane B2/analogs & derivatives , Thromboxane B2/urine , beta-Thromboglobulin/analysis , Adult , Biomarkers/blood , Biomarkers/urine , Female , Humans , Pregnancy/physiology , Reference Values
SELECTION OF CITATIONS
SEARCH DETAIL
...